H-CYTE Names Michael Yurkowsky Chief Executive Officer

3 years ago

TAMPA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of…

DLH Reports Fiscal 2021 Fourth Quarter Results

3 years ago

Q4 Revenue of $65.2 Million; Full Year Revenue $246.1 Million, up 17.6% over fiscal 2020; Debt Reduced to $46.8 MillionATLANTA,…

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

3 years ago

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing…

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

3 years ago

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,…

Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

3 years ago

Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicanna’s self-emulsifying drug delivery systems (SEDDS)…

CloudMD Graduates to the OTCQX; Begins Trading Today Under “DOCRF”

3 years ago

VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)…

ECMOHO Limited Announces the Appointment of independent director of the Board

3 years ago

SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider…

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

3 years ago

Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06,…

Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market

3 years ago

- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with…

Avalo Appoints Two New Independent Directors to Its Board

3 years ago

WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision…